Letter to Editor: Response to AASLD Editorial/Message from the President
- PMID: 30276829
- DOI: 10.1002/hep.30298
Letter to Editor: Response to AASLD Editorial/Message from the President
Abstract
A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
Comment in
-
Reply.Hepatology. 2019 May;69(5):2301. doi: 10.1002/hep.30564. Hepatology. 2019. PMID: 30762891
Comment on
-
Comments on cochrane review on direct-acting antivirals for hepatitis C.Hepatology. 2017 Oct;66(4):1016-1019. doi: 10.1002/hep.29366. Epub 2017 Aug 26. Hepatology. 2017. PMID: 28714142 No abstract available.
-
Direct-acting antivirals for chronic hepatitis C.Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012143. doi: 10.1002/14651858.CD012143.pub3. Cochrane Database Syst Rev. 2017. PMID: 28922704 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
